{"id":"W2989612821","doi":"10.1093/annonc/mdz426.039","title":"ENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Olaparib; Pembrolizumab; Oncology; Chemotherapy; Ovarian cancer; Epithelial ovarian cancer; Internal medicine; Gynecology; Cancer; Immunotherapy; Poly ADP ribose polymerase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001111111,0.0007388009,0.00134449,0.0002922617,0.0003073733,0.001141282,0.0008540262,0.0008112955,0.004997526],"category_scores_gemma":[0.000650734,0.0003582042,0.0009726723,0.0002762024,0.0005959592,0.0007447844,0.000287636,0.003845102,0.0009523337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009523809,"about_ca_system_score_gemma":0.001219742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001529932,"about_ca_topic_score_gemma":0.005044437,"domain_scores_codex":[0.9998273,0.00006271729,0.000007818296,0.0000287951,0.00001842175,0.00005488678],"domain_scores_gemma":[0.9997129,0.00005189216,0.00003699435,0.00001878018,0.00001306926,0.0001663986],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.476092,0.02990534,0.005513085,0.002531243,0.002839678,0.0003081475,0.0003851851,0.003871432,0.03819695,0.001644209,0.01965502,0.4190578],"study_design_scores_gemma":[0.7612504,0.2054457,0.01261145,0.0001852272,0.001012421,0.000441237,0.0001375738,0.003257795,0.003811918,0.0006716265,0.01112072,0.00005401677],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791612,0.008120144,0.0006522441,0.002082026,0.0006353262,0.00145662,0.001697083,0.0003074693,0.005887884],"genre_scores_gemma":[0.9813108,0.00514017,0.001622611,0.001823762,0.000188523,0.0010238,0.002922846,0.00005269556,0.005914673],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004997526,"threshold_uncertainty_score":0.01671839,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05193308591041664,"score_gpt":0.3914863836132615,"score_spread":0.3395532977028449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}